EGFR+ NSCLC

A retrospective study in EGFR+ NSCLC with brain metastases – Clinical Lung Cancer

Clinical Lung Cancer shared a post on X about a recent paper by Wesley Wong et al. published in Clinical Lung Cancer:

“A retrospective study in EGFR+ NSCLC with brain metastases shows that continuing osimertinib and chemo after progression reduces CNS progression vs. chemo alone.

CNS-PFS was longer (9.0 vs. 5.7 months), and salvage brain RT rates were lower (15% vs. 24%).”

“CNS outcomes of osimertinib plus chemotherapy in patients with EGFR mutation positive lung cancer beyond osimertinib progression”

Authors: Wesley Wong, Kevin Mok, Giselle Tsui, Tony Mok, Molly Li et al.

A retrospective study in EGFR+ NSCLC with brain metastases - Clinical Lung Cancer

More posts featuring Clinical Lung Cancer.

cancer Clinical Lung Cancer EGFR+ NSCLC Giselle Tsui Kevin Mok Molly Li OncoDaily Oncology Tony Mok Wesley Wong